B of A Securities Maintains Buy on Travere Therapeutics, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Greg Harrison maintains a Buy rating on Travere Therapeutics and raises the price target from $18 to $19.
September 06, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Travere Therapeutics and increased the price target from $18 to $19, indicating positive sentiment and potential upside.
The reaffirmation of a Buy rating and an increase in the price target by a reputable analyst suggests confidence in Travere Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100